Cancer imaging training in the 21st century: An overview of where we are, and where we need to be

Journal of the American College of Radiology

Volumn 12, Issue 7, 2015, Pages 714-720

  Howard, Stephanie A ^a,b,c   Krajewski, Katherine M ^a,b,c   Weissman, Barbara N ^b,c   Seltzer, Steven E ^b,c   Ramaiya, Nikhil H ^a,b,c   Van Den Abbeele, Annick D ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer imaging; oncoradiology; residency curriculum

Indexed keywords

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GENETICS; CANCER STATISTICS; CURRICULUM; DIAGNOSTIC IMAGING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE QUALITY; HISTOLOGY; HUMAN; ONCOLOGIST; RADIOLOGIST; RESIDENCY EDUCATION; REVIEW; SYSTEMIC DISEASE; EDUCATION; FORECASTING; GENOMICS; MEDICAL EDUCATION; NEOPLASMS; ONCOLOGY; RADIOLOGY; TRENDS;

EDUCATION, MEDICAL; FORECASTING; GENOMICS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; RADIOLOGY;

EID: 84937422285     PISSN: 15461440     EISSN: 1558349X     Source Type: Journal    
DOI: 10.1016/j.jacr.2015.03.044     Document Type: Article

References (31)

1. American Cancer Society. Facts and figures 2014. Accessed November, 2014. Available at: www.cancer.org.
2. A.B. Mariotto, K.R. Yabroff, Y. Shao, E.J. Feuer, and M.L. Brown Projections of the cost of cancer care in the United States: 2010-2020 J Natl Cancer Inst 103 2011 117 128
3. E.H. Ng, R.E. Pollock, M.F. Munsell, E.N. Atkinson, and M.M. Romsdahl Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging Ann Surg 215 1992 68 77
4. G.D. Demetri, M. von Mehren, C.D. Blanke, and et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480
5. A.D. Van den Abbeele, and R.D. Badawi Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs) Eur J Cancer 38 Suppl 5 2002 S60 S65
6. D.M. Jackman, V.A. Miller, L.A. Cioffredi, and et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials Clin Cancer Res 15 2009 5267 5273
7. D. Ercan, K. Zejnullahu, K. Yonesaka, and et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor Oncogene 29 2010 2346 2356
8. A.B. Cortot, and P.A. Janne Molecular mechanisms of resistance in epidermal growth factor receptor - mutant lung adenocarcinomas Eur Respir Rev 23 2014 356 366
9. O. Metzger-Filho, T. Vora, and A. Awada Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends Exp Op Investig Drugs 19 Suppl 1 2010 S31 S39
10. R.A. Pazo Cid, and A. Anton Advanced HER2-positive gastric cancer: current and future targeted therapies Crit Rev Oncol/Hematol 85 2013 350 362
11. M. Yan, B.A. Parker, R. Schwab, and R. Kurzrock HER2 aberrations in cancer: implications for therapy Cancer Treat Rev 40 2014 770 780
12. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, and et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
13. T. Tirkes, M.A. Hollar, M. Tann, M.D. Kohli, F. Akisik, and K. Sandrasegaran Response criteria in oncologic imaging: review of traditional and new criteria Radiographics 33 2013 1323 1341
14. M. Nishino, A. Giobbie-Hurder, M. Gargano, M. Suda, N.H. Ramaiya, and F.S. Hodi Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements Clin Cancer Res 19 2013 3936 3943
15. M. Nishino, H. Hatabu, B.E. Johnson, and T.C. McLoud State of the art: response assessment in lung cancer in the era of genomic medicine Radiology 271 2014 6 27
16. European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
17. R.L. Wahl, H. Jacene, Y. Kasamon, and M.A. Lodge From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 Suppl 1 2009 122S 150S
18. M.J. van den Bent, J.S. Wefel, D. Schiff, and et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas Lancet Oncol 12 2011 583 593
19. C.H. Holdsworth, R.D. Badawi, J.B. Manola, and et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor AJR Am J Roentgenol 189 2007 W324 W330
20. K.M. Krajewski, M. Nishino, Y. Franchetti, N.H. Ramaiya, A.D. Van den Abbeele, and T.K. Choueiri Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria Cancer 120 2014 711 721
21. H. Choi, C. Charnsangavej, S.C. Faria, and et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 2007 1753 1759
22. A.G. Ramsay Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity Brit J Haematol 162 2013 313 325
23. J.D. Wolchok, H. Kluger, M.K. Callahan, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
24. K.N. O'Regan, J.P. Jagannathan, N. Ramaiya, and F.S. Hodi Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy AJR Am J Roentgenol 197 2011 W241 W246
25. M. Nishino, S. Cardarella, S.E. Dahlberg, and et al. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors Lung Cancer 79 2013 283 288
26. G.J. Riely, M.G. Kris, B. Zhao, and et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus Clin Cancer Res 13 2007 5150 5155
27. A.D. van den Abbeele, YJ, D.S. Graze, J. Walker, and G.D. Demetri Inhibition and flare patterns of metabolic response to the Heat Shock Protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy (abstr) J Clin Oncol [Internet] 25 18S Part 1 2007 [3530 p.] Available at: http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/25/18-suppl/3530
28. H. Tsao, L. Chin, L.A. Garraway, and D.E. Fisher Melanoma: from mutations to medicine Genes Devel 26 2012 1131 1155
29. K.M. Mahoney, A. Ackerman, D.C. Cho, D.F. McDermott, T. Peters, and M.B. Atkins Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication J Clin Oncol 31 2013 e364 e366
30. S.A. Howard, K.M. Krajewski, E. Thornton, and et al. Decade of molecular targeted therapy: abdominal manifestations of drug toxicities - what radiologists should know AJR Am J Roentgenol 199 2012 58 64
31. E. Thornton, S.A. Howard, J. Jagannathan, and et al. Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients Brit J Radiol 85 2012 1420 1426